Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor
activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or
Nivolumab on patients and their pancreatic cancer.